Dr. Agrawal’s lab is devoted to the study of the genetics and molecular diagnostics of head and neck cancer. The group has described the genomic landscape of head & neck squamous cell carcinoma, esophageal cancer and medullary thyroid cancer, and has developed assays using tumor DNA as a biomarker in saliva and plasma. His lab’s research is focused on the application of cancer genetics to design diagnostic approaches to reduce morbidity and mortality from head and neck cancer.
Memorial Sloan Kettering Cancer Center
New York, NY
Fellowship - Head and Neck Surgical Oncology
2008
Johns Hopkins University
Baltimore, MD
Post-doc - Molecular Genetics
2007
Johns Hopkins University
Baltimore, MD
Residency - Otolaryngology-Head and Neck Surgery
2007
Johns Hopkins University
Baltimore, MD
MD - Medicine
2001
Rutgers University
New Brunswick, NJ
BA - Biology
1997
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer.
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
PMID: 40423530
Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207]. Oral Oncol. 2025 Oct; 169:107510.
PMID: 40721367
Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA. Oral Oncol. 2025 Aug; 167:107445.
PMID: 40578243
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
PMID: 40048190
Effects of ex vivo machine perfusion on preservation time and donor age in donation after brain death heart transplantation.
Effects of ex vivo machine perfusion on preservation time and donor age in donation after brain death heart transplantation. J Heart Lung Transplant. 2025 May; 44(5):830-835.
PMID: 40047739
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
PMID: 40043423
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands.
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
PMID: 39794830
Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects.
Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects. Acad Oncol. 2024; 1(2).
PMID: 39867572
A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. Neuro Oncol. 2024 Oct 03; 26(10):1895-1911.
PMID: 38981018
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
PMID: 38842838
Editorial Board
PLOS ONE
2019
AACR Team Science Award, American Association for Cancer Research
AACR
2017
Expert Panel, Early Detection (Screening) of Oral Cancer Clinical Practice Guidelines, American Dent
ADA
2016 - 2017
Reviewer (member)
NIH Cancer Genetics Study Section
2016
Senior Faculty Scholar, Bucksbaum Institute for Clinical Excellence
University of Chicago
2016
Editorial Board
Scientific Reports
2015
George T Nager Award for Excellence in Teaching
Johns Hopkins University
2012
Owsei Temkin Scholarship
Johns Hopkins University
2001
Richard Westcott Appleton Scholarship
Johns Hopkins University
2001
Johns Hopkins University School of Medicine Scholarship
Johns Hopkins University
1999
Marvin Harold Cheiten Award (1st in class), Rutgers University
Rutgers University
1997